N/A
N=39
Managing Insulin With a Voice AI
Medication Adherence
Bottom Line
View on ClinicalTrials.gov: NCT05081011 ↗Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: Time to Optimal Insulin Dose — 56; 15 days — p=0.006
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Voice Assistant Device (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Optimal Insulin Dose |
56; 15 | 0.006 sig |
| PRIMARY Insulin Medication Adherence |
50.2; 82.9 | 0.01 sig |
| PRIMARY Attitudes Toward Diabetes |
6.5; 8.4; 1.7; -1.9 | 0.03 sig |
| PRIMARY Attitudes Toward Health Technology |
6.6; 7.1; -1.1; 0.3 | 0.06 |
| PRIMARY Attitudes Toward Medication Adherence |
13.6; 14.0; -0.1; 0.8 | 0.46 |
| SECONDARY Percentage of Participants Who Achieved Glycemic Control |
25.0; 81.3 | 0.005 sig |
| SECONDARY Glycemic Improvement |
145.9; 167.5; 23.0; -45.9 | 0.001 sig |
Summary
This study randomizes participants to have their basal insulin titrated either through standard of care or by receiving prompts through interactions with an AI-enabled smart speaker device. The primary objective of this study is to investigate the feasibility of an AI-enabled smart speaker device and whether such a device facilitates insulin titration management, increases insulin adherence and decreases time to optimal insulin dose. The secondary objective of the study is to explore whether the device improves glycemic control as defined by improvements in fasting blood sugar.
Eligibility Criteria
Inclusion Criteria
- Patients with Type 2 Diabetes
- Patients clinically indicated to be taking daily long-acting insulin
- Patients currently taking long-acting insulin but necessitating active dose adjustments
Exclusion Criteria
- Patients who do not speak English
- Patients who do not own a smart phone
- Patients who do not have stable wireless internet connection at home
Data sourced from ClinicalTrials.gov (NCT05081011). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.